sodium phenylbutyrate

FDA Drug Profile — Buphenyl, BUPHENYL, OLPRUVA, sodium phenylbutyrate

sodium phenylbutyrate is listed in the FDA National Drug Code directory with 12 NDC codes, marketed under brand names including Buphenyl, BUPHENYL, OLPRUVA. Available dosage forms: pellet, powder, tablet, kit.

Drug details

Generic Name
sodium phenylbutyrate
Brand Names
Buphenyl, BUPHENYL, OLPRUVA, sodium phenylbutyrate
Application Number
NDA020573
Sponsor
Rottendorf Pharma GmbH
NDC Codes
12
Dosage Forms
PELLET, POWDER, TABLET, KIT
Routes
ORAL
Active Ingredients
SODIUM PHENYLBUTYRATE

Indications and Usage

1 INDICATIONS AND USAGE PHEBURANE is indicated as adjunctive therapy to standard of care, which includes dietary management, for the chronic management of adult and pediatric patients with urea cycle disorders (UCDs), involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC) or argininosuccinic acid synthetase (AS). Limitations of Use Episodes of acute hyperammonemia may occur in patients while on PHEBURANE. PHEBURANE is not indicated for the treatment of acute hyperammonemia, which can be a life-threatening medical emergency that requires rapid acting interventions to reduce plasma ammonia levels. PHEBURANE is a nitrogen-binding agent indicated as adjunctive therapy to standard of care, which includes dietary management, for the chronic management of adult and pediatric patients with urea cycle disorders (UCDs), involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC) or argininosuccinic acid synthetase (AS). ( 1 ) Limitations of Use PHEBURANE is not indicated for the treatment of acute hyperammonemia. ( 1 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.